Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

  • Andrea FarolfiEmail author
  • Pietro Ghedini
  • Stefano Fanti
Review Article


The aim of the review is to highlight articles published in 2017 in the Annals of Nuclear Medicine, an official peer-reviewed journal of the Japanese Society of Nuclear Medicine. Among all published manuscripts during the past year, we conducted a subjective selection of the most relevant topics. Fourteen fascinating articles are included in this review, ranging in topic from preclinical to clinical arenas.


Review PSMA 18F-FDG 11C-methionine 18F-FBPA Theranostics 



The authors received no specific funding for this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by the authors.


  1. 1.
    Carrió I, Kinuya S. New section in EJNMMI and Annals of Nuclear Medicine. Ann Nucl Med. 2016;30(9):593.CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  3. 3.
    Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med. 2015;29(10):877–82.CrossRefGoogle Scholar
  4. 4.
    Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31(9):696–702.CrossRefGoogle Scholar
  5. 5.
    Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–4.CrossRefGoogle Scholar
  6. 6.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31(9):709–17.CrossRefGoogle Scholar
  7. 7.
    Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94.CrossRefGoogle Scholar
  8. 8.
    Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2015;56(5):668–74.Google Scholar
  9. 9.
    Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017;31(7):521–8.CrossRefGoogle Scholar
  10. 10.
    Koizumi M, Wagatsuma K, Miyaji N, Murata T, Miwa K, Takiguchi T, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29(2):138–48.CrossRefGoogle Scholar
  11. 11.
    Koizumi M, Miyaji N, Murata T, Motegi K, Miwa K, Koyama M, et al. Evaluation of a revised version of computer-assisted diagnosis system, BONENAVI version 2.1.7, for bone scintigraphy in cancer patients. Ann Nucl Med. 2015;29(8):659–65.CrossRefGoogle Scholar
  12. 12.
    Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):783–95.CrossRefGoogle Scholar
  13. 13.
    Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.CrossRefGoogle Scholar
  14. 14.
    El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn. 2009;42(6):1162–71.CrossRefGoogle Scholar
  15. 15.
    Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.CrossRefGoogle Scholar
  16. 16.
    Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.PubMedGoogle Scholar
  17. 17.
    Heryanto Y-D, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med. 2017;31(9):669–77.CrossRefGoogle Scholar
  18. 18.
    Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685–91.CrossRefGoogle Scholar
  19. 19.
    Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23(3):175–80.CrossRefGoogle Scholar
  20. 20.
    Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(10):3375–9.CrossRefGoogle Scholar
  21. 21.
    Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, et al. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med. 2017;31(10):719–25.CrossRefGoogle Scholar
  22. 22.
    Takahashi M, Soma T, Mukasa A, Koyama K, Arai T, Momose T. An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using 18F-FDG-PET and 11C-methionine PET. Ann Nucl Med. 2017;31(3):250–9.CrossRefGoogle Scholar
  23. 23.
    Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med Off Publ Soc Nucl Med. 1998;39(5):778–85.Google Scholar
  24. 24.
    de Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med Off Publ Soc Nucl Med. 2005;46 Suppl 1:13S–17S.Google Scholar
  25. 25.
    Kunikowska J, Pawlak D, Bąk MI, Kos-Kudła B, Mikołajczak R, Królicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31(5):347–56.CrossRefGoogle Scholar
  26. 26.
    Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27(7):867–869.CrossRefGoogle Scholar
  27. 27.
    Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40(2):213–27.CrossRefGoogle Scholar
  28. 28.
    Yamamoto H, Arimura S, Nakanishi A, Shimo Y, Motoi Y, Ishiguro K, et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. Ann Nucl Med. 2017;31(5):407–12.CrossRefGoogle Scholar
  29. 29.
    Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med Off Publ Soc Nucl Med. 2009;50(10):1638–45.Google Scholar
  30. 30.
    Imabayashi E, Soma T, Sone D, Tsukamoto T, Kimura Y, Sato N, et al. Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer’s disease using brain perfusion SPECT. Ann Nucl Med. 2017;31(7):536–43.CrossRefGoogle Scholar
  31. 31.
    Imabayashi E, Yokoyama K, Tsukamoto T, Sone D, Sumida K, Kimura Y, et al. The cingulate island sign within early Alzheimer’s disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer’s disease from dementia with Lewy bodies. EJNMMI Res. 2016;6(1):67.CrossRefGoogle Scholar
  32. 32.
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2003;61(9):1115–7.CrossRefGoogle Scholar
  33. 33.
    Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 1939. 2011;142(11):1243–51.CrossRefGoogle Scholar
  34. 34.
    Schauwecker DS. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol. 1992;158(1):9–18.CrossRefGoogle Scholar
  35. 35.
    Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento Maxillo Facial Radiol. 2006;35(4):236–43.CrossRefGoogle Scholar
  36. 36.
    Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2009;67(5 Suppl):75–84.CrossRefGoogle Scholar
  37. 37.
    O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2009;67(7):1363–72.CrossRefGoogle Scholar
  38. 38.
    Thomas C, Spanidis M, Engel C, Roos FC, Frees S, Neisius A, et al. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). Clin Oral Investig. 2016;20(4):753–8.CrossRefGoogle Scholar
  39. 39.
    Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med. 2011;36(1):17–20.CrossRefGoogle Scholar
  40. 40.
    Watanabe S, Nakajima K, Mizokami A, Yaegashi H, Noguchi N, Kawashiri S, et al. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. Ann Nucl Med. 2017;31(3):201–10.CrossRefGoogle Scholar
  41. 41.
    Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 2008;35(10):1803–11.CrossRefGoogle Scholar
  42. 42.
    Masaki Y, Shimizu Y, Yoshioka T, Tanaka Y, Nishijima K-I, Zhao S, et al. The accumulation mechanism of the hypoxia imaging probe ‘FMISO’ by imaging mass spectrometry: possible involvement of low-molecular metabolites. Sci Rep. 2015;5:16802.CrossRefGoogle Scholar
  43. 43.
    Masaki Y, Shimizu Y, Yoshioka T, Nishijima K-I, Zhao S, Higashino K, et al. FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state. Ann Nucl Med. 2017;31(8):596–604.CrossRefGoogle Scholar
  44. 44.
    Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2009;67(7–8 Suppl):S348–50.Google Scholar
  45. 45.
    Watabe T, Hanaoka K, Naka S, Kanai Y, Ikeda H, Aoki M, et al. Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET. Ann Nucl Med. 2017;31(6):481–5.CrossRefGoogle Scholar
  46. 46.
    Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4(1):70.CrossRefGoogle Scholar
  47. 47.
    Lasnon C, Salomon T, Desmonts C, Dô P, Oulkhouir Y, Madelaine J, et al. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Ann Nucl Med. 2017;31(2):125–34.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018
corrected publication 2018

Authors and Affiliations

  1. 1.Metropolitan Nuclear MedicineS.Orsola-Malpighi Hospital, University of BolognaBolognaItaly

Personalised recommendations